Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 24, 2007 Brian Lawler	Neurocrine in the Green 2006 wasn't kind to the drug developer, but whatever happens with indiplon, Neurocrine's management deserves kudos for keeping investors well informed on the status of the drug and where the company stands as far as timelines go.
The Motley Fool February 6, 2008 Brian Lawler	Neurocrine on the Upswing? Neurocrine Bioscience releases year-end numbers, and updates investors on the status of its top drugs.
The Motley Fool June 15, 2007 Brian Lawler	Neurocrine Moves Ahead Neurocrine resubmits a marketing application for its lead drug. Investors, take note.
The Motley Fool December 14, 2007 Brian Lawler	FDA Knocks Neurocrine a Knuckle Sandwich The FDA clobbers drugmaker Neurocrine with another delay.
The Motley Fool August 1, 2007 Brian Lawler	Neurocrine Awaits Its Destiny Neurocrine Biosciences updates investors on its plans for the rest of the year. A new marketing application was submitted for lead drug indiplon, following a negative FDA decision last year. Good news could come as soon as December 2007.
The Motley Fool September 5, 2006 Brian Lawler	Neurocrine Wakes Up Indiplon The biotech company announces new drug delays. Investors, take note.
The Motley Fool November 6, 2006 Brian Lawler	Neurocrine's Big Headache Another clinical trial means a steep drop in share price, but the biopharmaceutical's not dead yet. Investors, take note.
The Motley Fool May 8, 2007 Brian Lawler	Neurocrine Is Waking Up After being put to sleep for much of 2006 following an unexpected FDA smackdown on its lead drug, indiplon, shares of the biopharma have boosted over 50% higher versus its lows last year.
The Motley Fool February 17, 2005 Karl Thiel	Sleeping on Neurocrine's Shares Why haven't Neurocrine Biosciences shares moved? It's partly history, with delays in getting an insomnia drug to market.
BusinessWeek June 12, 2006 Catherine Arnst	Going From The Lab To Limbo The FDA has been delaying decisions on applications, and drugmakers are fuming.
The Motley Fool June 23, 2006 Stephen D. Simpson	Neurocrine Biosciences: From Bad to Worse Pfizer's departure is a serious, though not fatal, blow to the biotech. While this story may yet have a happy ending, there's going to be a lot of nervous waiting between now and then. Investors, take note.
The Motley Fool June 18, 2010 Denise Gellene	San Diego's Neurocrine Biosciences Scores Second Big Deal in Two Days The San Diego biotech agreed to grant German drug maker Boehringer Ingelheim and signed a pact with Abbott Labs.
The Motley Fool May 16, 2006 Stephen D. Simpson	The FDA Tries to Put Neurocrine to Sleep A surprisingly worded rejection sends two stocks skidding. But setbacks aren't always terminal. While it won't be easy, Neurocrine Biosciences and DOV Pharmaceuticals investors may just want to hang on.
The Motley Fool August 12, 2008 Brian Lawler	The FDA Stands Up Cardiome What does the approvable letter mean for Cardiome and other drug developers?
The Motley Fool June 21, 2007 Brian Lawler	Pfizer Gets Held Up The FDA issues an approvable letter for its novel HIV compound. Investors, take note.
The Motley Fool October 8, 2010 Brian D. Pacampara	Neurocrine Popped: What You Need to Know While the possibility of a big return exists, know that Neurocrine, as is the case with all baby biotechs, can plunge just as hard.
The Motley Fool October 8, 2007 Charly Travers	Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics...
The Motley Fool November 14, 2007 Brian Lawler	Is the FDA Still Approving New Drugs? Lately the FDA seems more reluctant to approve new drugs than it once was. Let's take a look at the actual numbers from the past eight years.
The Motley Fool August 13, 2004 Charly Travers	Smaller Market for Insomnia Drugs A market research report shows insurers might not cover some drugs for this condition.
The Motley Fool September 26, 2007 Brian Lawler	Following the Fallen Biotech Class of 2006 Let's take a look a list of the biggest development stage drugmaker disasters from 2006 and how the tiny drug developers have fared since they announced their clinical trial or regulatory failures.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool October 20, 2010 Matt Koppenheffer	Neurocrine Biosciences Shares Popped: What You Need to Know Shares of biotech Neurocrine Biosciences were up more than 10% in intraday trading on higher-than-average volume.
The Motley Fool August 17, 2007 Brian Orelli	Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.
The Motley Fool June 16, 2010 Brian Orelli	Double-Digit Rise on Doubling Its Cash Neurocrine Biosciences is seeing a nice boost to its stock price today -- some 14% -- after Abbott Labs agreed to license its endometriosis treatment, elagolix, and any future follow-on products.
The Motley Fool December 22, 2003 Alyce Lomax	Losing Faith in Inspire Delay for its dry-eye treatment leaves investors uninspired.
The Motley Fool July 21, 2006 Brian Lawler	Sepracor Stays Alert Insomnia drug Lunesta's sales growth is anything but sleepy. Despite the shares' ups and downs, Sepracor's most recent earnings suggest that its performance remains admirably steady.
The Motley Fool July 10, 2008 Brian Orelli	The Death of the Approvable Letter The name's changing, but for investors, little else will.
The Motley Fool June 27, 2008 Brian Lawler	Vanda's Drug Draws a Yawn Shares of Vanda Pharmaceuticals have fallen more than 20% recently, even though the company said that its phase 3 clinical trial met its primary goal.
The Motley Fool October 31, 2006 Brian Lawler	A Look Inside the Biotech Haunted House Even after being warned of the risks, if you're still brave enough to come inside the biotech haunted house, realize that there are surprises. For example, the FDA will spook investors with calls for more clinical trials on drugs that appear to be a lock for approval.
The Motley Fool March 9, 2004 David Nierengarten	Sepracor's No Sleeper FDA approval for its sleeping medication sends Sepracor's stock up 70%.
The Motley Fool October 10, 2005 Stephen D. Simpson	The FDA: Boon, Bane, Whipping Boy Everyone wants the FDA to be faster, better, and cheaper, but that may not be a credible expectation. Investors would do well to keep an eye on the FDA because its policies and pressures ultimately filter down to our medicine cabinets, wallets, and portfolios.
The Motley Fool October 26, 2004 Charly Travers	Sepracor's Tough Road to Profits Will insomnia drug Estorra take the company to the promised land?
The Motley Fool December 26, 2006 Brian Lawler	Barely a Ripple for New River With New River's $2 billion market cap, no recurring revenues to speak of, and the terms of its partnership with Shire still uncertain, these shares are more than a tad too rich.
The Motley Fool April 19, 2005 Stephen D. Simpson	Pfizer Fosters Fertile Future Results in the "here and now" aren't bad, but it will take a couple of years to build growth. Of course, investors must do their own research and make their own decisions.
The Motley Fool June 23, 2010 Kris Eddy	Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems.
BusinessWeek January 17, 2005 Weintraub & Barrett	Waking Up The Insomnia Market On Dec. 16, Sepracor Inc. won approval from the Food & Drug Administration to market Lunesta, a new sleep aid. Giddy investors pushed Sepracor's stock up 16%, to $60, in the two weeks following the news.
The Motley Fool April 26, 2006 Stephen D. Simpson	A Pain DOV Pharmaceutical Couldn't Cure A trial failure crushes the stock, but the game isn't over yet. Though there are risks aplenty here, there could still be value.
The Motley Fool July 7, 2006 Philip Durell	What to Do in a Down Market Sideways or even down markets can last for a considerable time, particularly if we see more indicators of a forthcoming economic recession. Yet this is no reason to get out of stocks.
The Motley Fool December 16, 2003 David Nierengarten	Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks.
The Motley Fool November 4, 2005 Stephen D. Simpson	A $99 Biotech Portfolio Can this biotech six-pack pay off for aggressive investors? Acadia Pharmaceuticals... Alexion Pharmaceuticals... Arena Pharmaceuticals... Crucell NV... DOV Pharmaceutical... Millennium Pharmaceuticals...